AstraZeneca responds to public comments made about the globalisation of our collaboration with the University of Oxford on a potential COVID-19 vaccine

Click here to view online. Add this email to your safelist.

15 May 2020

AstraZeneca can confirm that it is in discussions with the US Government on expanding potential supply for the US as part of its previously announced agreement for the development and worldwide manufacturing and distribution of Oxford University’s potential recombinant adenovirus vaccine known as ChAdOx1 nCoV-19, aimed at preventing COVID-19 infection from SARS-CoV-2.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.